Ann: Preliminary Final Report, page-4

Interesting points:
- "Net tangible assets per security at 30 Jun 2020 = 0.17 cents" (more than the current share price)!
- "The Company's COVID-19 risk severity test is in its final stages of development ....."
- "Commencing the creation of multi-test kits which will allow for risk testing five or more diseases in one kit ....."
- "The Company, importantly, has acquired new equipment which will allow for the establishment of comprehensive genetic risk tests which will combine monogenic and polygenic testing under a single banner of genetic risk stratification, covering 100% of a person’s genetic risk. This new equipment will also allow multi-testing for multiple disease risks with the Company's new arrays capable of studying up to 650,000 individual SNP at any one time. The new equipment will also allow the Company to enter the medical rebate testing space with tests for monogenic mutations and cancer sequencing attracting a rebate both in the US and Australia."
- "With the increased interest in genetic testing, there are a large number of small companies entering the risk stratification space. The Company is committed to outcomes, rather than just products - thus the Company is now actively looking to incorporate quality market ready genetic tests developed by credentialed groups to include on its CIT platforms."
- "Renewal of NATA and CLIA-accredited laboratory status for Australian and US markets."
- "PRS on Type 2 diabetes test completed."
- "In June, the Company received US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer. The Company is the first company in the world to successfully commercialise a polygenic risk test for breast cancer."